Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-059562
Filing Date
2026-05-20
Accepted
2026-05-20 16:31:09
Documents
81
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0290247-10q_aditxt.htm   iXBRL 10-Q 1116893
2 CERTIFICATION ea029024701ex31-1.htm EX-31.1 11614
3 CERTIFICATION ea029024701ex31-2.htm EX-31.2 11417
4 CERTIFICATION ea029024701ex32-1.htm EX-32.1 5154
  Complete submission text file 0001213900-26-059562.txt   8132753

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adtx-20260331.xsd EX-101.SCH 77675
6 XBRL CALCULATION FILE adtx-20260331_cal.xml EX-101.CAL 42953
7 XBRL DEFINITION FILE adtx-20260331_def.xml EX-101.DEF 402438
8 XBRL LABEL FILE adtx-20260331_lab.xml EX-101.LAB 686674
9 XBRL PRESENTATION FILE adtx-20260331_pre.xml EX-101.PRE 424043
85 EXTRACTED XBRL INSTANCE DOCUMENT ea0290247-10q_aditxt_htm.xml XML 947327
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39336 | Film No.: 261004494
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)